CHAPTERS
- 0:00 – 1:47
RFK Jr. at HHS and the "roaches" of corporate capture
Joe and Brigham open by framing the moment as a power shift: RFK Jr. taking charge at HHS and forcing long-protected interests into the open. Brigham sets the tone by describing how deep regulatory capture runs across health-related agencies.
- •Rogan’s optimism about RFK Jr. leading HHS and pushing reform (including peptides)
- •Brigham’s background: pharma rep, med device, lab owner, preventive care advocate
- •Claim that corruption/collusion spans FDA, NIH, CDC, EPA, and more
- •The scale of HHS makes rapid change slow and politically fraught
- 1:47 – 5:22
Vaccine policy flashpoint: CDC resignation and Hep B shots for babies
The conversation quickly moves to a recent CDC resignation and debates around infant vaccination policy. They argue incentives and mandates often follow revenue, not risk-based logic.
- •CDC official resigns; Rogan highlights optics and controversy
- •Questioning rationale for Hepatitis B vaccines in newborns
- •Argument that policy incentives are profit-driven
- •Broader theme: public-health messaging vs financial motives
- 5:22 – 6:49
Inside the FDA meeting: "They’ll smile… and screw you"
Brigham recounts a Kennedy-arranged meeting with FDA staff that seemed cordial—until an insider warned him the agency would ignore the concerns. This kicks off a detailed critique of how FDA decisions are shaped by industry narratives and funding.
- •RFK Jr. sets up Brigham’s FDA meeting to represent compounders/telemedicine/regenerative medicine
- •Insider warning: friendly demeanor masking unchanged agenda
- •FDA’s reliance on industry input and user-fee funding (capture incentive)
- •Compounders as competition to pharma pricing and access models
- 6:49 – 10:39
GLP-1s, compounding, and dosing incentives: why side effects spike
They zoom into GLP-1 drugs (Ozempic/Wegovy equivalents) as the test case for capture: patents, access, and reimbursement. Brigham argues many harms come from dose escalation driven by formularies rather than patient-specific optimization.
- •GLP-1s as peptides; precedent-setting battle for the entire peptide category
- •Claim: insurance reimbursement incentivizes higher doses and faster titration
- •Compounders’ approach: micro-dosing, personalization, add-on peptides
- •Example stack: GLP-1 + IGF-1 LR3 to preserve muscle and bone density
- 10:39 – 20:46
Manufacturing hypocrisy and the "backorder list" data fight
Brigham challenges the pharma narrative that compounded products are unsafe by pointing to FDA warning letters against major manufacturers and alleged inspection gaps. He also describes a large-scale pharmacy availability audit used to dispute the FDA’s claim that shortages were resolved.
- •Claims: Novo/Eli Lilly have FDA warning letters; broader inspection backlog issues
- •Argument that compounders can be inspected more often than large manufacturers
- •FDA shortage/backorder list as a “bat signal” for compounding exemptions
- •Brigham’s claim: 30,000-pharmacy outreach showed low availability of lower doses
- 20:46 – 28:50
The bigger play: reclassifying drugs as biologics to lock out competition
Brigham alleges pharma is attempting to reclassify widely used therapies as biologics to extend monopoly protection and eliminate compounding entirely. This becomes his central warning about how pricing reform can be sidestepped via regulatory definitions.
- •Thyroid meds example: push to label animal-derived thyroid as a biologic
- •Biologic exclusivity framed as longer protection vs traditional drugs (12 years cited)
- •Key consequence: biologics generally cannot be compounded under FDA stance
- •Claim: this would cripple telemedicine and compounding competition
- 28:50 – 47:22
Court documents, legacy staff, and RFK’s "Whac-A-Mole" enforcement problem
They describe hidden policy changes via court filings and internal resistance from long-tenured employees. Brigham claims RFK intervened after being alerted, forcing emergency calls and issuing mandates to keep peptide access open through compliant channels.
- •Alleged FDA stance in court: “no medical necessity for peptides”
- •Revolving-door influence and legacy employee resistance
- •Brigham contacts RFK; rapid escalation to FDA calls and follow-up meetings
- •Concern: banning legit access fuels black-market peptides and a new crisis
- 47:22 – 49:53
Captured science and psychiatry: SSRIs, screening tools, and placebo-level benefits
The discussion pivots to mental health, arguing diagnostic tools and drug narratives were built to expand prescribing, not clarify biology. Brigham and Rogan claim SSRIs barely outperform placebo while lifestyle interventions show stronger effects.
- •No objective blood/brain test for depression/ADHD; subjectivity of questionnaires
- •“Chemical imbalance” narrative framed as pharma marketing (claimed disproven)
- •SSRI efficacy claim: ~2 points above placebo on a depression scale
- •Exercise and red-light therapy cited as stronger-than-drug effects
- 49:53 – 1:01:06
ADHD questionnaires in real time, childhood labels, and lifestyle as medicine
Rogan takes an ADHD self-report scale live, illustrating how context changes answers—and how easily meds can be justified. Brigham shares his own childhood experience being mislabeled and argues movement, training, and purpose can be protective.
- •Live walk-through of an ADHD self-report scale and scoring ambiguity
- •Rogan’s point: environment/job satisfaction shapes “symptoms”
- •Brigham’s story: dyslexia/ADHD, nearly medicated, placed in “pre-first”
- •Exercise as stabilizer for anxiety; kids as “human puppies” in classrooms
- 1:01:06 – 1:18:10
Texas MAHA bills: lobbying warfare over food stamps, school lunches, and labels
Brigham describes state-level legislative battles to reduce ultra-processed food harms—met by intense lobbying from major corporations and health NGOs. They detail the political tactics used to reframe health reforms as discriminatory or harmful to communities.
- •Bills targeting SNAP/school lunch ultra-processed foods and nutrition education
- •Lobby opposition includes major brands and associations (e.g., AHA cited)
- •Vote success in Senate followed by heavy lobbying pressure in House
- •Outcome: labeling wins for banned substances, but chemical exposure issues persist
- 1:18:10 – 1:50:48
Glyphosate, Monsanto, and the push for legal immunity from future lawsuits
The focus turns to agricultural chemicals, arguing regulators and lawmakers are being pressured to shield manufacturers from liability. They connect U.S. exposure levels, differences with Europe, and claims about end-of-harvest spraying practices.
- •Federal push alleged: immunity for glyphosate/atrazine-related claims
- •Monsanto history invoked (Agent Orange/DDT references)
- •Claim: much glyphosate exposure comes from pre-harvest “drying” sprays
- •National security angle: supply chains and chemical sourcing linked to China
- 1:50:48 – 1:56:37
Personal outcomes and regenerative toolkits: dementia, obesity, bloodwork, and vision
They share anecdotes of patient improvement using a stack of interventions—hyperbaric therapy, peptides, stem cells, red light, and personalized supplementation. The segment frames “preventative and personalized” care as the alternative to insurance-driven sick care.
- •Dementia anecdote involving Jesse Michels’ father and short-term cognitive improvement
- •Jelly Roll’s weight-loss story and emphasis on muscle preservation/body composition
- •Rogan’s personalized vitamin protocol and reported improvement in eyesight
- •Broader toolkit: peptides (GHK/BPC), stem cells, PRP, hyperbaric, red light
- 1:56:37 – 3:11:43
From UFOs to AI: engineered humans, surveillance states, and the next species transition
The conversation broadens into speculation: UAP materials, interdimensional theories, biotech, and AI convergence. They discuss surveillance tools, deepfakes, CRISPR gene editing, neural interfaces, and the fear that humanity is being pushed toward integration with machines.
- •Gary Nolan/UAP materials claims and what would be hard to fabricate historically
- •AI-driven surveillance and privacy concerns (Israel, Palantir, predictive policing fears)
- •CRISPR and gene-editing arms race; “superhuman” optimization pressures
- •Neural interfaces, VR realism, and the argument that decentralization is essential
- 3:11:43 – 3:20:07
Peru tridactyl mummies, ancient architecture, and the "what if it’s real" conclusion
They close by revisiting Jesse Michels’ coverage of Peru’s tridactyl mummies and related anomalies, arguing it challenges the reflexive “hoax” dismissal. The episode ends with a mix of wonder, uncertainty, and a final wrap-up and plug.
- •Tridactyl mummy scans as the strongest “pause and reconsider” evidence in their view
- •Connections to Nazca lines, Machu Picchu, and unexplained stonework
- •Speculation: genetic relationship to humans; idea of engineered origins
- •Wrap-up, gratitude, and Ways2Well mention
